001     137589
005     20240229105111.0
024 7 _ |a 10.1073/pnas.1720564115
|2 doi
024 7 _ |a pmid:29895693
|2 pmid
024 7 _ |a pmc:PMC6042091
|2 pmc
024 7 _ |a 0027-8424
|2 ISSN
024 7 _ |a 1091-6490
|2 ISSN
024 7 _ |a altmetric:43641438
|2 altmetric
037 _ _ |a DKFZ-2018-01469
041 _ _ |a eng
082 _ _ |a 000
100 1 _ |a Correia, Margareta P
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential.
260 _ _ |a Washington, DC
|c 2018
|b National Acad. of Sciences
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1659613705_16657
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a CD8+ T cells are considered prototypical cells of adaptive immunity. Here, we uncovered a distinct CD8+ T cell population expressing the activating natural killer (NK) receptor NKp30 in the peripheral blood of healthy individuals. We revealed that IL-15 could de novo induce NKp30 expression in a population of CD8+ T cells and drive their differentiation toward a broad innate transcriptional landscape. The adaptor FcεRIγ was concomitantly induced and was shown to be crucial to enable NKp30 cell-surface expression and function in CD8+ T cells. FcεRIγ de novo expression required promoter demethylation and was accompanied by acquisition of the signaling molecule Syk and the 'innate' transcription factor PLZF. IL-15-induced NKp30+CD8+ T cells exhibited high NK-like antitumor activity in vitro and were able to synergize with T cell receptor signaling. Importantly, this population potently controlled tumor growth in a preclinical xenograft mouse model. Our study, while blurring the borders between innate and adaptive immunity, reveals a unique NKp30+FcεRIγ+CD8+ T cell population with high antitumor therapeutic potential.
536 _ _ |a 314 - Tumor immunology (POF3-314)
|0 G:(DE-HGF)POF3-314
|c POF3-314
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a FCER1G, human
|2 NLM Chemicals
650 _ 7 |a NCR3 protein, human
|2 NLM Chemicals
650 _ 7 |a Natural Cytotoxicity Triggering Receptor 3
|2 NLM Chemicals
650 _ 7 |a Receptors, Fc
|2 NLM Chemicals
700 1 _ |a Stojanovic, Ana
|0 P:(DE-He78)6459232320662d60ee842fd348128d87
|b 1
|u dkfz
700 1 _ |a Bauer, Katharina
|0 P:(DE-He78)5b10e57ed1df98e2fd31edbdeed985ba
|b 2
|u dkfz
700 1 _ |a Juraeva, Dilafruz
|0 P:(DE-He78)5482b9f7e4c4ff6a3a4d7c860a1bce61
|b 3
|u dkfz
700 1 _ |a Tykocinski, Lars-Oliver
|b 4
700 1 _ |a Lorenz, Hanns-Martin
|b 5
700 1 _ |a Brors, Benedikt
|0 P:(DE-He78)fc949170377b58098e46141d95c72661
|b 6
|u dkfz
700 1 _ |a Cerwenka, Adelheid
|0 P:(DE-He78)d2b4dd8bdffe4aaa0f5e30e91587766f
|b 7
|e Last author
|u dkfz
773 _ _ |a 10.1073/pnas.1720564115
|g Vol. 115, no. 26, p. E5980 - E5989
|0 PERI:(DE-600)1461794-8
|n 26
|p E5980 - E5989
|t Proceedings of the National Academy of Sciences of the United States of America
|v 115
|y 2018
|x 1091-6490
909 C O |p VDB
|o oai:inrepo02.dkfz.de:137589
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)6459232320662d60ee842fd348128d87
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)5b10e57ed1df98e2fd31edbdeed985ba
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)5482b9f7e4c4ff6a3a4d7c860a1bce61
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)fc949170377b58098e46141d95c72661
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)d2b4dd8bdffe4aaa0f5e30e91587766f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-314
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Tumor immunology
|x 0
914 1 _ |y 2018
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b P NATL ACAD SCI USA : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b P NATL ACAD SCI USA : 2015
920 1 _ |0 I:(DE-He78)D080-20160331
|k D080
|l Nachwuchsgruppe Angeborene Immunität
|x 0
920 1 _ |0 I:(DE-He78)G200-20160331
|k G200
|l Angewandte Bioinformatik
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D080-20160331
980 _ _ |a I:(DE-He78)G200-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21